Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xience and HeartMate II panel dates set

This article was originally published in The Gray Sheet

Executive Summary

FDA confirms that its Circulatory System Devices Advisory panel will review the PMA for Abbott's Xience V everolimus-eluting coronary stent on Nov. 29 and the PMA for Thoratec's HeartMate II left ventricular assist system as a bridge to transplant Nov. 30 in Gaithersburg, Md. Abbott will present two-year follow-up data from 500 patients in its SPIRIT II and SPIRIT III clinical trials (1"The Gray Sheet" Oct. 29, 2007, p. 6). Thoratec's application is based on data from a study of 279 patients
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025486

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel